Rigel Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Rigel Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
Rigel Pharmaceuticals, Inc. Selects Onco360 Oncology Pharmacy As A National Pharmacy Partner For VEPPANU (Vepdegestrant)
The story matters when it changes Rigel Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
The story matters when it changes Rigel Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Rigel Pharmaceuticals, Inc.: Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
The story matters when it changes Rigel Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Investors are testing whether Rigel Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript
Investors are testing whether Rigel Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call Transcript
Investors are testing whether Rigel Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Call Transcript
Investors are testing whether Rigel Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest RIGL filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Rigel Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →